Foley Hoag’s highly trained, respected, and experienced patent prosecution professionals can meet your legal needs at many levels. We believe that strategic counsel for developing and managing intellectual property is essential to your ability to succeed in an increasingly sophisticated and competitive marketplace. And our clients’ success is our ultimate goal. learn more

News more

  • Foley Hoag Welcomes Raj Vallabh, Intellectual Property Counsel  [Read More]
  • On the Agenda: Law and the Environment, Financing Growth, and Non-Competes—Foley Hoag Launches Three New Blogs  [Read More]
  • Foley Hoag Welcomes Susie Ahn, Health Policy Specialist  [Read More]
  • Summer @ Foley Hoag LLPFoley Hoag Launches New Microsite for Law Students as 2009 On-campus Interviews Commence  [Read More]
  • Working Mother and Flex-Time Lawyers Recognize Foley Hoag  [Read More]

Publications more

  • .TEL Domain Name Registration Begins December 3, 2008 [Read More]
  • In re Bilski: Trouble Ahead for Biotech? [Read More]
  • Coverage and Reimbursement for Molecular Diagnostics: Current Issues and Options [Read More]
  • EEC Perspectives - October 2008 [Read More]
  • Failure to Obtain Opinion of Counsel May Be Evidence of Intent to Induce Infringement [Read More]

Events more

December 2, 2008 Life Sciences Presentation: A Call to Arms - Data Standards in Collaborative Research [Read More] Emerging Enterprise Center at Foley Hoag
Waltham, MA

Client Successes more

  • Global Bio-Chem Technology Group Company Limited
    Our lawyers, in conjunction with Adduci, Mastriani & Schaumberg LLP and East Associates, represented Global Bio-Chem Technology Group Company Limited and its affiliates (GBT), the largest lysine producer in China and the largest vertically integrated corn-based biochemical manufacturer in Asia, which prevailed after an evidentiary hearing before the United States International Trade Commission (USITC) in a patent infringement investigation brought by Ajinomoto Heartland LLC and Ajinomoto Co., Inc. (Ajinomoto). In a ruling in July 2008, the Administrative Law Judge (ALJ) held that the claims of Ajinomoto’s two patents were invalid for failure to disclose the best mode of practicing the invention, thus finding no violation of Section 337 of the Tariff Act of 1930. The ALJ also ruled that both patents were unenforceable because Ajinomoto had committed inequitable conduct. [Read More]
  • Driving Biopharma Forward
    Our lawyers identified, on the eve of FDA approval of one of our client's biopharmaceuticals, a prior public use that would cause a court to invalidate the otherwise blocking patent claims. This enabled our client to negotiate a license under the patent on commercially reasonable terms. [Read More]